文献速递创伤骨科骨质疏松与代谢性骨病

骨质疏松症及骨质疏松药物对骨折愈合的影响:一篇叙述性综述

Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review.
PubMed 文献 · Osteoporos Int · 2024-04-08

国际骨质疏松基金会(IOF)骨折工作组撰写的叙述性综述,评估骨质疏松症及抗骨质疏松药物对骨折愈合的影响。综述结论认为抗骨吸收药物对人类骨折愈合无不良影响,特立帕肽可能缩短某些部位骨折的愈合时间,罗莫索单抗在动物中的有益作用未在人类中观察到。

要点

  • 抗骨吸收药物对人类骨折愈合无不良影响,急性脆性骨折后无需延迟启动抗骨吸收治疗。
  • 特立帕肽可能缩短某些部位(如桡骨远端)的骨折愈合时间,但不预防骨不连或影响愈合率。
  • 罗莫索单抗在动物中显示的促进骨折愈合作用未在人类中观察到。

核心结论

  • 总体而言,骨质疏松药物对骨折愈合似乎没有不良影响。
  • 应优先考虑治疗骨质疏松症的获益以及减轻骨折后即将发生的再骨折风险的紧迫必要性。
  • 必须确定新的骨折愈合放射学和生物学标志物,并整合临床与基础科学方法学以评估骨折愈合。

研究设计与样本

  • 由国际骨质疏松基金会(IOF)科学顾问委员会骨折工作组成员撰写、代表IOF与国际矫形外科与创伤学会(SICOT)的叙述性综述。

主要发现

  • 动物数据支持骨质疏松症对骨折愈合有负面影响,但临床数据似乎并不支持这一点。
  • 证据不支持在急性脆性骨折后延迟启动抗骨吸收治疗。
  • 如果患者已在接受骨质疏松药物治疗,骨折时没有理由暂停用药。
  • 特立帕肽治疗可能缩短某些部位如桡骨远端的骨折愈合时间,但不预防骨不连或影响愈合率。
  • 罗莫索单抗在动物中显示的促进骨折愈合作用未在人类中观察到。

关键数值与推荐

  • 骨痂形成、桥接骨小梁和骨折线随时间缩小表明愈合,影像学必须结合临床参数和患者报告结局。

临床怎么用

  • 原文结论未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Antiresorptive medications do not negatively affect fracture healing in humans. Teriparatide may decrease time to fracture healing. Romosozumab has not shown a beneficial effect on human fracture healing. BACKGROUND: Fracture healing is a complex process. Uncertainty exists over the influence of osteoporosis and the medications used to treat it on fracture healing. METHODS: Narrative review authored by the members of the Fracture Working Group of the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF), on behalf of the IOF and the Société Internationale de Chirurgie Orthopédique et de Traumatologie (SICOT). RESULTS: Fracture healing is a multistep process. Most fractures heal through a combination of intramembranous and endochondral ossification. Radiographic imaging is important for evaluating fracture healing and for detecting delayed or non-union. The presence of callus formation, bridging trabeculae, and a decrease in the size of the fracture line over time are indicative of healing. Imaging must be combined with clinical parameters and patient-reported outcomes. Animal data support a negative effect of osteoporosis on fracture healing; however, clinical data do not appear to corroborate with this. Evidence does not support a delay in the initiation of antiresorptive therapy following acute fragility fractures. There is no reason for suspension of osteoporosis medication at the time of fracture if the person is already on treatment. Teriparatide treatment may shorten fracture healing time at certain sites such as distal radius; however, it does not prevent non-union or influence union rate. The positive effect on fracture healing that romosozumab has demonstrated in animals has not been observed in humans. CONCLUSION: Overall, there appears to be no deleterious effect of osteoporosis medications on fracture healing. The benefit of treating osteoporosis and the urgent necessity to mitigate imminent refracture risk after a fracture should be given prime consideration. It is imperative that new radiological and biological markers of fracture healing be identified. It is also important to synthesize clinical and basic science methodologies to assess fracture healing, so that a convergence of the two frameworks can be achieved.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Chandran M, Akesson KE, Javaid MK, et al. Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review. Osteoporos Int. 2024. PMID: 38587674. doi:10.1007/s00198-024-07059-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。